-
CancelDate：2020-12
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=535CEC Capital Group serves as exclusive financial advisor Beijing Haosi (Health) Biotechnology Co., Ltd. (hereinafter referred to as "Haosi Bio" or the "Company"), a leading provider of solutions for clinical mass spectrometry detection, today announced th
-
Cancel -
CancelDate：2020-12
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=508GaiaWorks (the “Company”), a workforce management cloud service provider, announced that it has completed its RMB 500 million Series D1 financing round, led by GGV Capital. Tencent Holdings, EDBI, and Index Capital China also participated in the round. Previous shareholders Matrix Partners China also increased their holdings in the Company.
-
CancelDate：2020-11
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=525Tea brand CHALI (the “Company”) recently announced the closing of a Series B financing round of RMB 100 million. This round of financing was led by Country Garden Venture Capital, with CEC Capital Group’s investment fund and Wens (Guangdong) also participating in this round of investment. The proceeds from the financing will primarily be used for channel expansion and the construction of the Company’s Nansha R&D center. CHALI was established in August 2013. The Company is positioned as a packaged tea products and retail store brand. Its main products include herbal and fruit blended teas with over 600 million tea bags sold. During this year’s Double 11 Festival (November 11) in China, CHALI’s online sales ranked third in T-mall’s tea category and first in the herbal tea category. On JD.com, CHALI’s Peach Oolong Tea pouch sold 140,000 units, ranking No. 1 in single product sales in JD’s tea categories.
-
CancelDate：2020-11
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=516Huiyihuiying (the “Company”) a leader in medical imaging artificial intelligence, announced that it has successfully completed its latest round (Series C2) of hundreds of millions of RMB in financing, one of the largest financings in the healthcare AI industry in China. This round of financing included new investors Shougang Fund, Sinopharm Junbai, and Kunjian Xintai, and existing shareholders including CDH Investments, Datai Capital, and Lanchi Ventures. CEC Capital Group served as the exclusive financial advisor of Huiyihuiying in this transaction.
-
CancelDate：2020-11
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=530Beijing Megarobo Technologies Co., Ltd. (“Megarobo” or the “Company”) has recently completed a USD 30 million Series B financing round. This round of financing was led by Sinovation Ventures. Followers in the round included Liando Investment and existing shareholders Joy Capital and Robert Bosch Venture Capital. CEC Capital Group acted as the exclusive financial advisor of Megarobo in this transaction. Proceeds from this round will primarily be used to expand Megarobo’s core business, R&D efforts, the Company’s laboratory facilities, and to continue to build up the Company’s core capabilities in the field of life science automation.
-
Cancel -
CancelDate：2020-10
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=5043DMed Diagnostic (the “Company”), a leader in the field of accurate tumor diagnosis in China, recently completed a financing of RMB 280 million for its diagnostics business segment. The financing round was jointly led by China Resources Pharmaceutical Industry Investment Fund, Shandong Luxin High-tech Industry Co. Ltd., and the Shandong Transportation Industry Development Fund. After serving as exclusive financial advisor for 3D Medicines, the parent company of 3DMed Diagnostic, in its first round of financing, CEC Capital Group continued to serve as exclusive financial advisor for the first round of financing for 3DMed Diagnostic after it was spun-off from the parent company.
-
CancelDate：2020-09
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=529MEDx Translational Medicine (Suzhou) Co., Ltd. (hereinafter referred to as “MEDx Translational Medicine” or the “Company”) recently announced the completion of RMB 350 million in Series B financing. This round of financing was led by existing shareholder Qiming Venture Partners. Followers of the round included Sinopharm Capital, Tsing Song Capital and Broad Resources. Existing investors Quan Capital and Anjie Investment also expanded their holdings within the Company. This round of financing will primarily be used to expand the Company’s translation medicine platform, increase the R&D of diagnostic products, accelerate product registration and sales networks, expand overseas R&D and service capabilities, and expand commercial marketing efforts. The Company is aiming to better support domestic and international pharmaceutical companies in developing innovative drugs and precision medication for cancer patients.
Scan to log in to WeChatLog in on phone to use WeChat on Web
京公網安備 11010102004518號